Updated On: 23 October, 2021 10:45 AM IST | Washington | IANS
The data show that the two-dose primary series of the vaccine given to children from 5 to less than 12 years of age confers a high degree of protective efficacy against Covid-19 during a period when the Delta variant of concern predominates in the US

Photo for representational purpose. Pic/ AFP
Pfizer and its partner BioNTech said their Covid-19 vaccine is safe and 90.7 per cent effective against symptomatic coronavirus in children aged 5 to 11.
The companies revealed the data in a document posted on Friday ahead of a meeting of advisers to the Food and Drug Administration (FDA) scheduled for October 26.